Anika Therapeutics (ANIK) 50.32 $ANIK Integra (IART)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anika Therapeutics (ANIK) 50.32 $ANIK

Integra (IART) Tops Q2 Earnings, Grows Organically, Ups View
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 3:05PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 79 cents in the second quarter of 2016.
IART: 84.35 (-0.24), FCSC: 1.05 (+0.03), ANIP: 61.06 (unch), ANIK: 50.32 (-0.32)

Anika Reports Second Quarter 2016 Financial Results
BusinessWire - Wed Jul 27, 3:05PM CDT
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today reported financial results for the second quarter ended June 30, 2016, along with business progress in the period.
ANIK: 50.32 (-0.32)

Global Market for Regenerative Medicine & Stem Cells - What's hot, what's not, what's next by 2019?
GlobeNewswire - Wed Jul 27, 8:30AM CDT
The competitive landscape of the global regenerative medicine market includes players such as CONMED Corporation, Anika Therapeutics Inc., Arthrex, Inc., Baxter International Inc., Smith & Nephew PLC, DePuySynthes Inc., Stryker Corporation, Medtronic Inc., and Zimmer Holdings Inc. Though North America and Europe were the largest markets for regenerative medicines, the market players are increasingly shifting their focus on the emerging economies across Asia Pacific such as India, South Korea, Japan, and China. These countries are registering an increased demand for various bone and joint reconstructive products such as Osteocel Plus (NuVasive Inc.), Trinity Evolution (Orthofix Inc.), and INFUSE Bone Graft (Medtronic Inc.) owing to the rapid growth of the healthcare sector and the rising pool of patients. The market players are investing in rigorous research and development initiatives for innovative products.
SNN: 33.43 (+0.25), MDT: 87.81 (-0.25), BAX: 48.61 (+0.11), ANIK: 50.32 (-0.32), NUVA: 62.90 (-0.39), SYK: 116.49 (-0.53)

5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 300.69 (-1.14), JNJ: 124.93 (-0.47), VRTX: 97.69 (-0.51), MDCO: 38.78 (-0.25), AMGN: 174.27 (+0.11), GSK: 45.38 (+0.13), ANIK: 50.32 (-0.32)

Anika to Present at the Singular Research 11th Annual Spring Select Conference on June 9, 2016
BusinessWire - Thu Jun 02, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research 11th Annual Spring Select Conference on Thursday, June 9, 2016 at 2:30 pm PT. The conference is being held at the Hilton hotel in San Francisco, CA.
ANIK: 50.32 (-0.32)

Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BusinessWire - Wed Jun 01, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in the European Union. CINGAL, which will be initially available in Hungary, Czech Republic, Poland, Germany, and Italy, received CE Mark approval in March 2016 to treat pain associated with osteoarthritis. CINGAL will be marketed and sold in Europe by a network of experienced commercial partners under the terms of their respective commercialization agreements.
ANIK: 50.32 (-0.32)

Anika Therapeutics Announces Canadian Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee
BusinessWire - Thu May 19, 8:05AM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today announced the commercial launch of CINGAL(R), its third-generation viscosupplement, in Canada. CINGAL received Health Canada approval in October 2015 to treat pain associated with osteoarthritis of the knee.
ANIK: 50.32 (-0.32)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 48.09 (-2.36), OMED: 12.53 (+0.10), LGND: 136.67 (-1.86), ANIK: 50.32 (-0.32)

Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:40PM CDT
Alexion (ALXN) reported earnings of 87 cents per share, below the Zacks Consensus Estimate of 91 cents.
EBS: 30.99 (+0.02), ALXN: 132.23 (-1.27), AEGR: 1.48 (+0.01), ANIK: 50.32 (-0.32)

Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 84.35 (-0.24), ANIP: 61.06 (unch), ANIK: 50.32 (-0.32), ALQA: 1.12 (-0.04)

GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:06PM CDT
Glaxo (GSK) reported first-quarter 2016 core earnings of 57 cents per American depositary share, missing the Zacks Consensus Estimate of 60 cents.
EBS: 30.99 (+0.02), GSK: 45.38 (+0.13), ANIK: 50.32 (-0.32), NVS: 83.09 (+0.02)

Baxalta (BXLT) Beats on Q1 Earnings, Set to Merge with Shire
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:41AM CDT
Baxalta's (BXLT) first-quarter 2016 earnings of 47 cents per share beat the Zacks Consensus Estimate by a penny.
BAX: 48.61 (+0.11), SHPG: 203.17 (+9.17), BXLT: 46.02 (-0.18), ANIK: 50.32 (-0.32)

Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:27AM CDT
Bristol-Myers' (BMY) first-quarter 2016 earnings (excluding special items) of 74 cents per share easily beat the Zacks Consensus Estimate of 66 cents.
EBS: 30.99 (+0.02), PFE: 36.51 (-0.80), BMY: 75.44 (-0.75), ANIK: 50.32 (-0.32)

Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:05AM CDT
Celgene Corp. (CELG) reported first-quarter 2016 earnings of $1.18 per share (including share-based compensation expense), beating the Zacks Consensus Estimate of $1.05.
EBS: 30.99 (+0.02), AEGR: 1.48 (+0.01), ANIK: 50.32 (-0.32), CELG: 113.96 (-0.73)

Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 7:15AM CDT
Immunomedics Inc. (IMMU) shares rose almost 11% in the last trading session.
IMMU: 2.79 (-0.01), ANIK: 50.32 (-0.32)

Downgrade Alert for Anika Therapeutics (ANIK)
Comtex SmarTrend(R) - Thu Apr 28, 3:36AM CDT
Anika Therapeutics (NASDAQ:ANIK) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $44.64 on volume of 513,000 shares, above average daily volume of 148,000. There is potential upside of 14.2% for shares of Anika Therapeutics based on a current price of $44.64 and an average consensus analyst price target of $51.00. Anika Therapeutics shares have support at the 50-day moving average (MA) of $44.62 and additional support at the 200-day MA of $38.85.
ANIK: 50.32 (-0.32)

Anika beats 1Q profit forecasts
Automated Insights - Wed Apr 27, 4:05PM CDT
BEDFORD, Mass. (AP) _ Anika Therapeutics Inc. (ANIK) on Wednesday reported first-quarter earnings of $6.9 million.
ANIK: 50.32 (-0.32)

Anika Reports First Quarter 2016 Financial Results
BusinessWire - Wed Apr 27, 3:05PM CDT
--Commenced $25 million Accelerated Share Repurchase Program
ANIK: 50.32 (-0.32)

Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:57AM CDT
Bayer (BAYRY) reported core earnings of $2.61 per share, above the Zacks Consensus Estimate of $2.48.
CYTX: 2.12 (-0.05), AEGR: 1.48 (+0.01), ANIK: 50.32 (-0.32)

New Strong Buy Stocks for April 27th
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:41AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ALGN: 89.85 (+0.16), AMCX: 55.49 (+0.05), AEGR: 1.48 (+0.01), ANIK: 50.32 (-0.32), ADTN: 18.02 (-0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 53

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 569

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 84

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 113

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Mastering Prescription Labels: Critical Insights for Safety

Updated Category News Views 0

Revolutionizing How We Approach Prescription Labels Prescription labels aren't just scraps of paper or stickers slapped on bottles; they're lifelines. The insight from pharmacy expert Sheldon Birch could turn a regular label into a powerful tool for health management. According to Birch, the label is often disregarded yet speaks volumes about the medication you've got in...

Continue Reading

Top 5 Most Recently Viewed Articles

Ray Dalio Warns of Economic Heart Attack and Gold Investment

Updated Category News Views 330

Debt-Fueled Risks in the U.S. Economy Ray Dalio, founder of Bridgewater Associates, has recently shared his concerns regarding the growing debt burden facing the U.S. economy. According to Dalio, this financial strain resembles arterial blockage, leading to the possibility of a severe economic "heart attack." His warning speaks volumes as the national debt continues to...

Continue Reading
Citi Projects Stronger Global Economic Growth in 2024

Updated Category News Views 249

Global Economic Outlook for 2024 In a recent report, Citi's group of economists has expressed optimism about the global economic scene for 2024. They predict that the economy will exceed earlier expectations, thanks in part to lower interest rates and positive trends emerging from several markets. These elements create a more encouraging environment for growth compared to...

Continue Reading
Quarterhill Welcomes David Charron as CFO to Drive Growth

Updated Category News Views 226

David Charron Takes the Helm as Quarterhill's CFO Quarterhill Inc. (TSX: QTRH) is excited to announce that David Charron has been appointed as the new Chief Financial Officer (CFO). This strategic move comes as the company gears up for its next phase of growth. David brings over 15 years of experience in leadership roles within public technology companies, making him a...

Continue Reading
Autolus Therapeutics: Key Insights Ahead of Earnings Release

Updated Category News Views 209

Overview of Autolus Therapeutics Earnings Report Autolus Therapeutics (NASDAQ: AUTL) is preparing to share its quarterly earnings results soon. Investors are keenly anticipating this announcement, which will give them a clearer picture of the company’s performance and future direction. Forecasts and Market Expectations Analysts are projecting a loss per share (EPS) of...

Continue Reading
Blue Diamond Growers Earns Star Site Award for Safety Excellence

Updated Category News Views 299

Blue Diamond Growers Achieves Recognition for Safety Standards Blue Diamond Growers, the leading cooperative in almond marketing and processing, has reached a significant milestone by receiving the "Star Site" designation from Cal/OSHA. This recognition is awarded to employers who have excelled in managing safety and health programs effectively. Exceptional Safety at the...

Continue Reading